Cerliponase alfa treatment shows extended efficacy for CLN2 disease
Cerliponase alfa treatment slows the progression of neuronal ceroid lipofuscinosis type 2 disease for at least 5 years, shows an open-label extension study in The Lancet Neurology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
